Pegylated liposomal doxorubicin (PLD) in heavily pretreated epithelial ovarian cancer patients

被引：0
|
作者：
Gorumlu, Gurbuz [1 ]
Kucukzeybek, Yuksel [1 ]
Karabulut, Bulent [1 ]
Terek, Mustafa C. [1 ]
Uslu, Ruchan [1 ]
Sanli, Ulus A. [1 ]
Akman, Levent [1 ]
Ozsaran, Aydin [1 ]
Dikmen, Yilmaz [1 ]
Goker, Erdem [1 ]
机构：
[1] Ege Univ, Izmir, Turkey
来源：
ANNALS OF ONCOLOGY | 2006年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：172 / 172
页数：1
相关论文
共 50 条
  • [1] Pegylated liposomal doxorubicin in heavily pretreated epithelial ovarian cancer patients
    Gorumlu, G.
    Kucukzeybek, Y.
    Kemal-Gul, M.
    Karaca, B.
    Cosan-Terek, M.
    Karabulut, B.
    Sanli, U. A.
    Akman, L.
    Ozsaran, A.
    Dikmen, Y.
    Uslu, R.
    JOURNAL OF BUON, 2008, 13 (03): : 349 - 352
  • [2] Role of pegylated liposomal doxorubicin (PLD) in epithelial ovarian cancer
    Lorusso, D
    Ferrandina, G
    Lo Voi, R
    Fagotti, A
    Scambia, G
    JOURNAL OF CHEMOTHERAPY, 2004, 16 : 98 - 103
  • [3] Pegylated liposomal doxorubicin in patients with epithelial ovarian cancer
    Zhen Yuan
    Ying Zhang
    Dongyan Cao
    Keng Shen
    Qingshui Li
    Guonan Zhang
    Xiaohua Wu
    Manhua Cui
    Ying Yue
    Wenjun Cheng
    Li Wang
    Pengpeng Qu
    Guangshi Tao
    Jianqing Hou
    Lixin Sun
    Yuanguang Meng
    Guiling Li
    Changzhong Li
    Huirong Shi
    Yaqing Chen
    Journal of Ovarian Research, 14
  • [4] Pegylated liposomal doxorubicin in patients with epithelial ovarian cancer
    Yuan, Zhen
    Zhang, Ying
    Cao, Dongyan
    Shen, Keng
    Li, Qingshui
    Zhang, Guonan
    Wu, Xiaohua
    Cui, Manhua
    Yue, Ying
    Cheng, Wenjun
    Wang, Li
    Qu, Pengpeng
    Tao, Guangshi
    Hou, Jianqing
    Sun, Lixin
    Meng, Yuanguang
    Li, Guiling
    Li, Changzhong
    Shi, Huirong
    Chen, Yaqing
    JOURNAL OF OVARIAN RESEARCH, 2021, 14 (01)
  • [5] Effects of weekly bevacizumab and pegylated liposomal doxorubicin in heavily pretreated patients with recurrent or progressed ovarian cancer
    Kikuchi, Y., Sr.
    Kouta, H.
    Kikuchi, R.
    Takano, M.
    Kita, T.
    Kudoh, K.
    Aoki, D.
    Sugiyama, T.
    Isonishi, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [6] PROLONGED TREATMENT WITH TRABECTIN PLUS PEGYLATED LIPOSOMAL DOXORUBICIN (PLD) COMBINATION IN A HEAVILY PRETREATED PATIENT WITH METASTATIC RELAPSED OVARIAN CANCER (ROC)
    Guillet, P.
    Beedassy, B.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2015, 25 (09) : 1369 - 1369
  • [7] Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer
    Newhouse, Rebecca
    Nelissen, Ellen
    El-Shakankery, Karim Hussien
    Rogozinsk, Ewelina
    Bain, Esme
    Veiga, Susana
    Morrison, Jo
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2023, (07):
  • [8] Pegylated liposomal doxorubicin for relapsed epithelial ovarian cancer
    Lawrie, Theresa A.
    Bryant, Andrew
    Cameron, Alison
    Gray, Emma
    Morrison, Jo
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2013, (07):
  • [9] Phase II study of pegylated liposomal doxorubicin in heavily pretreated epithelial ovarian cancer patients - May a new treatment schedule improve toxicity profile?
    Lorusso, D
    Naldini, A
    Testa, A
    D'Agostino, G
    Scambia, G
    Ferrandina, G
    ONCOLOGY, 2004, 67 (3-4) : 243 - 249
  • [10] Efficacy and toxicity of extended duration pegylated liposomal doxorubicin (PLD) in women with recurrent epithelial ovarian cancer
    Chambers, L. Moulton
    Pendlebury, A. B.
    Yao, M.
    Rose, P. G.
    DeBernardo, R.
    GYNECOLOGIC ONCOLOGY, 2020, 159 : 107 - 108
12345